Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

被引：0
|
作者：
Horn, L. [1 ]
Wakelee, H. [2 ]
Blumenschein, G. [3 ]
Reckamp, K. [4 ]
Waqar, S. [5 ]
Carter, C. A. [6 ]
Gitlitz, B. J. [7 ]
Infante, J. R. [8 ]
Sanborn, R. E. [9 ]
Neal, J. [2 ]
Gockerman, J. P. [10 ]
Dukart, G. [11 ]
Harrow, K. [11 ]
Liang, C. [11 ]
Gibbons, J. J. [11 ]
Hernandez, J. [12 ]
Newman-Eerkes, T. [12 ]
Lim, L. [12 ]
Lovly, C. [1 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Thorac Oncol, Nashville, TN USA
[2] Stanford Univ, Med Ctr, Med Oncol, Stanford, CA 94305 USA
[3] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA
[4] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA
[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[6] Natl Naval Med Ctr, Thorac Oncol, Bethesda, MD USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA
[8] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[9] Providence Portland Med Ctr, Thorac Oncol Program, Portland, OR USA
[10] Novella Clin, Oncol, Morristown, NC USA
[11] Xcovery Holding Co, Oncon, Palm Beach Gardens, FL USA
[12] Resolut Biosci, Clin Operat, Bellevue, WA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1210PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Provencio, Mariano
    Izquierdo, Angel
    Vinolas, Nuria
    Paz-Ares, Luis
    Feliu, Jaime
    Constenla, Manuel
    de las Heras, Begona
    Erustes, Mercedes
    Izquierdo, Miguel A.
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [32] The phase II ASCEND-7 (CLDK378A2205) trial: Ceritinib in patients (pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) metastatic to the brain and/or leptomeninges
    Wolf, J.
    Schneider, C-P
    Potzner, M.
    Arratia, Cazorla P.
    Shen, J.
    Branle, F.
    von Pawel, J.
    Oncology Research and Treatment, 2015, 38 : 138 - 138
  • [33] Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
    Veluswamy, R.
    Bhalla, S.
    Samstein, R.
    Marron, T.
    Gomez, J. E.
    Doroshow, D. B.
    Sabari, J.
    Shum, E.
    Saxena, A.
    Namakydoust, A.
    Chachoua, A.
    Wisnivesky, J.
    Mandeli, J.
    Bhardwaj, N.
    Hirsch, F. R.
    Merad, M.
    Reddy, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1020
  • [34] Crizotinib safety profile in elderly and non-elderly patients (pts) with advanced ALK plus non-small cell lung cancer (NSCLC)
    Blackhall, F.
    Shaw, A. T.
    Jaenne, P. A.
    Kim, D. W.
    Wilner, K. D.
    Schnell, P.
    Polli, A.
    Besse, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S821 - S821
  • [35] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [36] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Valerie Israel
    Scott T. Tagawa
    Terry Snyder
    Susan Jeffers
    Derek Raghavan
    Investigational New Drugs, 2004, 22 : 291 - 297
  • [37] Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)
    Israel, V
    Tagawa, ST
    Snyder, T
    Jeffers, S
    Raghavan, D
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 291 - 297
  • [38] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
    Reckamp, K. L.
    Wakelee, H. A.
    Patel, S.
    Blumenschein, G.
    Neal, J. W.
    Gitlitz, B.
    Waqar, S. N.
    Tan, F.
    Harrow, K.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345